SLRX Stock Overview
A clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Salarius Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.55 |
| 52 Week High | US$7.20 |
| 52 Week Low | US$1.22 |
| Beta | 0.92 |
| 1 Month Change | 13.14% |
| 3 Month Change | 0% |
| 1 Year Change | -67.55% |
| 3 Year Change | -98.51% |
| 5 Year Change | -99.80% |
| Change since IPO | -99.93% |
Recent News & Updates
Recent updates
Salarius pharmaceuticals announces 1-for-25 reverse stock split
Oct 14Salarius adds 12% after updates on clinical programs and financials
Sep 13Salarius Pharma adds two Mayo Clinic sites to phase 1/2 trial of Seclidemstat as treatment for cancers
Aug 22Salarius Pharmaceuticals GAAP EPS of -$0.09 beats by $0.01
Aug 08Salarius Pharmaceuticals and VolitionRx enter into R&D collaboration agreement
Aug 02Salarius Pharma reports new seclidemstat results in Ewing sarcoma and other solid tumors at ASCO21
Jun 07Salarius Pharmaceuticals (SLRX) Investor Presentation - Slideshow
May 27Salarius Pharmaceuticals (NASDAQ:SLRX) Shareholders Have Enjoyed An Impressive 155% Share Price Gain
Feb 09
Salarius Pharmaceuticals receives second installment of $1.7M in payments
Jan 13Salarius Pharma raises $3.5M via warrant exercise
Dec 11Salarius Pharmaceuticals EPS in-line, beats on revenue
Nov 11Shareholder Returns
| SLRX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 11.8% | -3.8% | -2.7% |
| 1Y | -67.5% | -2.6% | 23.4% |
Return vs Industry: SLRX underperformed the US Biotechs industry which returned -2.6% over the past year.
Return vs Market: SLRX underperformed the US Market which returned 23.4% over the past year.
Price Volatility
| SLRX volatility | |
|---|---|
| SLRX Average Weekly Movement | 13.5% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.9% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: SLRX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: SLRX's weekly volatility has decreased from 22% to 14% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 2 | David Arthur | www.salariuspharma.com |
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors.
Salarius Pharmaceuticals, Inc. Fundamentals Summary
| SLRX fundamental statistics | |
|---|---|
| Market cap | US$2.23m |
| Earnings (TTM) | -US$4.99m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.4x
P/E RatioIs SLRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SLRX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$4.99m |
| Earnings | -US$4.99m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.47 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 11.2% |
How did SLRX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 09:45 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Salarius Pharmaceuticals, Inc. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Aydin Huseynov | Benchmark Company |
| Michael King | H.C. Wainwright & Co. |